The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00354627
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : June 12, 2015
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland

Brief Summary:
The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens. Information on safety and tolerability aspects of TMC125 in combination with other ARVs in treatment-experienced HIV-1 patients with limited treatment options will be assessed. Available data regarding the effectiveness of the drug will also be collected. To be eligible, patients should be failing their current ARV regimen or be on a treatment interruption, should have previously received 2 different protease inhibitor (PI) containing regimens and be at least 3-class experienced (protease inhibitors [PI], nucleoside/tide reverse transcriptase inhibitors [N[t]RTIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) or at least 2-class experienced (PIs and N[t]RTIs) with primary NNRTI resistance. TMC125 will be administered in combination with an investigator-selected background of additional ARVs from the list of allowed medications.

Condition or disease Intervention/treatment Phase
HIV-1 Drug: TMC125 Phase 3

Detailed Description:
This is an open label trial with primary objective to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected. Patients should be at least 3-class experienced or 2-class experienced with primary non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. They should also have previously received 2 different protease inhibitor-based regimens (low-dose ritonavir is not counted as a protease inhibitor (PI) regimen), be on a treatment interruption or not be virologically suppressed on their current regimen, and not be able to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance. Patients must also meet all in- and exclusion criteria. TMC125 (200mg twice daily) will be provided once the patient has been confirmed eligible for entry. Once treatment with TMC125 in combination with other ARVs has been initiated, patients must be instructed to follow the recommended visit schedule based on routine clinical care. Safety and tolerability of the entire antiretroviral therapy (ART) regimen, including TMC125, should be monitored by the investigator as per standard clinical practice. However, it is recommended that visits be planned 4 and 12 weeks following initiation of TMC125 in combination with other ARVs and every 12 weeks thereafter while on therapy during this trial. Adverse events (AEs) leading to treatment interruption or discontinuation and all serious adverse events (SAEs), with the exception of Acquired Immunodeficiency Syndrome (AIDS) defining illnesses (CDC class C) unless fatal or considered to be related to TMC125, will be collected. Other adverse events will be collected only if required as per local regulations. The background ARVs may be changed at any time during the trial, at the discretion of the investigator due to the development of resistance, intolerance, toxicity, etc. while continuing treatment with TMC125 if in the investigator's assessment the patient still benefits from treatment with TMC125. If changes in the background regimen are made, it is recommended that a follow-up visit be planned 4 weeks after the change in therapy. Treatment with investigational medication will be continued until virologic failure, treatment-limiting toxicity, subject lost to follow-up, patient's withdrawal, pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. Patients will be instructed to orally take two 100 mg tablets of TMC125 following a meal every 12 hours. TMC125 (200 mg twice daily) must be used in combination with other antiretroviral drugs. Treatment with investigational medication will continue until virologic failure, treatment-limiting toxicity, patient lost to follow-up, withdrawal, pregnancy, discontinuation of TMC125 development or when TMC125 becomes commercially available in the patient's country.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5178 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options
Study Start Date : January 2006
Actual Primary Completion Date : February 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Etravirine

Arm Intervention/treatment
Experimental: TMC125
TMC125 200 mg b.i.d. till commercially available.
Drug: TMC125
200 mg b.i.d. till commercially available.

Primary Outcome Measures :
  1. The primary objective of TMC125-C214 is to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. [ Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. ]

Secondary Outcome Measures :
  1. The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected. [ Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is at least 3-class experienced (3 classes of licensed oral antiretrovirals: nucleoside/tide reverse transcriptase inhibitors [N[t]RTI], protease inhibitors [PI], non-nucleoside reverse transcriptase inhibitors [NNRTI])
  • Patients with primary NNRTI resistance can be included if they are experienced with at least 2 classes of ARVs (PIs, N[t]RTIs) and meet all the other inclusion criteria
  • Patient has previously received 2 different PI-based regimens
  • Patient is unable to use currently approved NNRTIs due to resistance (primary or acquired) and/or intolerance
  • Patient, if currently receiving an ARV regimen, is not achieving adequate virologic suppression on his/her current regimen.

Exclusion Criteria:

  • Prior or current participation in DUET trials (TMC125-C206 or TMC125-C216).
  • Use of disallowed concomitant therapy, including disallowed antiretrovirals (ARV)
  • Use of investigational ARVs (with exceptions)
  • Any active clinically significant disease (e.g., cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that is not either resolved or stabilized for at least 30 days before the Screening Phase
  • Pregnant or breast-feeding female
  • Female patient of childbearing potential not using effective non-hormonal birth control methods
  • Patients with specific laboratory abnormalities
  • Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00354627

  Hide Study Locations
United States, Alabama
Anniston, Alabama, United States
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, California
Anaheim, California, United States
Arcata, California, United States
Bakersfield, California, United States
Beverly Hills, California, United States
Fontana, California, United States
Fountain Valley, California, United States
Garden Grove, California, United States
Harbor City, California, United States
Hayward, California, United States
Loma Linda, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Oakland, California, United States
Palm Springs, California, United States
Panorama City, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
San Mateo, California, United States
San Rafael, California, United States
Santa Ana, California, United States
Santa Clara, California, United States
Santa Clarita, California, United States
Santa Rosa, California, United States
Stanford, California, United States
Tarzana, California, United States
Ukiah, California, United States
Woodland Hills, California, United States
United States, Colorado
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
United States, Connecticut
Glastonbury, Connecticut, United States
New Haven, Connecticut, United States
Norwalk, Connecticut, United States
Norwich, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Daytona Beach, Florida, United States
Fort Lauderdale, Florida, United States
Fort Laudersale, Florida, United States
Ft Lauderdale, Florida, United States
Hollywood, Florida, United States
Labelle, Florida, United States
Leesburg, Florida, United States
Miami, Florida, United States
N Miami Beach, Florida, United States
North Palm Beach, Florida, United States
Orlando, Florida, United States
Pensacola, Florida, United States
Plantation, Florida, United States
Port St Lucie, Florida, United States
Safety Harbor, Florida, United States
Sarasota, Florida, United States
Tampa, Florida, United States
Tarpon Springs, Florida, United States
Vero Beach, Florida, United States
West Palm Beach, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Jessup, Georgia, United States
Macon, Georgia, United States
Riverdale, Georgia, United States
Savannah, Georgia, United States
Tucker, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Illinois
Aurora, Illinois, United States
Chicago, Illinois, United States
Maywood, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Iowa
Des Moines, Iowa, United States
Iowa City, Iowa, United States
United States, Kentucky
Henderson, Kentucky, United States
Paducah, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Maine
Ellsworth, Maine, United States
Portland, Maine, United States
United States, Maryland
Baltimore, Maryland, United States
Silver Spring, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Grand Rapids, Michigan, United States
Grosse Pointe Woods, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
Rochester, Minnesota, United States
Saint Louis Park, Minnesota, United States
United States, Missouri
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
United States, Nebraska
Lincoln, Nebraska, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Hampshire
Rochester, New Hampshire, United States
United States, New Jersey
Englewood, New Jersey, United States
Hackensack, New Jersey, United States
Long Branch, New Jersey, United States
Neptune, New Jersey, United States
Newark, New Jersey, United States
Perth Amboy, New Jersey, United States
Somers Point, New Jersey, United States
Voorhees, New Jersey, United States
Westfield, New Jersey, United States
United States, New Mexico
Santa Fe, New Mexico, United States
United States, New York
Briarcliff, New York, United States
Bronx, New York, United States
Brooklyn, New York, United States
Buffalo, New York, United States
East Meadow, New York, United States
Elmira, New York, United States
Flushing, New York, United States
Kingston, New York, United States
Manhasset, New York, United States
New York, New York, United States
Rochester, New York, United States
Staten Island, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Gastonia, North Carolina, United States
Huntersville, North Carolina, United States
Winston Salem, North Carolina, United States
United States, Ohio
Akron, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Allentown, Pennsylvania, United States
Johnstown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Providence, Rhode Island, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, Tennessee
Johnson City, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Dallas, Texas, United States
El Paso, Texas, United States
Fort Worth, Texas, United States
Harlingen, Texas, United States
Houston, Texas, United States
Longview, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Annandale, Virginia, United States
Charlottesville, Virginia, United States
Fairfax, Virginia, United States
Hampton, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Olympia, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Yakima, Washington, United States
United States, West Virginia
Charleston, West Virginia, United States
United States, Wisconsin
La Crosse, Wisconsin, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Antwerpen, Belgium
Brugge, Belgium
Brussels, Belgium
Bruxelles, Belgium
Charleroi, Belgium
Gent, Belgium
Leuven, Belgium
Liège, Belgium
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, New Brunswick
Moncton, New Brunswick, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Whitby, Ontario, Canada
Windsor, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Ste-Foy, Quebec, Canada
Aarhus, Denmark
Copenhagen, Denmark
Hvidovre N/A, Denmark
Odense N/A, Denmark
Aachen, Germany
Berlin, Germany
Bochum, Germany
Bonn, Germany
Düsseldorf, Germany
Erlangen, Germany
Essen, Germany
Frankfurt, Germany
Freiburg, Germany
Hamburg, Germany
Hannover, Germany
Koln, Germany
Köln, Germany
Mainz, Germany
Mannheim, Germany
Munich, Germany
München, Germany
Münster, Germany
Osnabrück, Germany
Stuttgart, Germany
Würzburg, Germany
Athens, Greece
Patra, Greece
Thessalonikis, Greece
Korea, Republic of
Kyungki, Korea, Republic of
Pusan, Korea, Republic of
Seoul, Korea, Republic of
Luxembourg, Luxembourg
Bosques Del Nogalar San Nicola, Mexico
Chihuahua, Mexico
Ciudad De Mexico, Mexico
Col Tacuba, Mexico
Guadalajara, Mexico
Mexico City, Mexico
Monterrey Nuevo León, Mexico
Puebla, Mexico
Tijuana, Mexico
Alkmaar, Netherlands
Amsterdam Zuidoost, Netherlands
Amsterdam, Netherlands
Arnhem, Netherlands
Den Haag, Netherlands
Groningen, Netherlands
Leiden, Netherlands
Maastricht, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands
Tilburg, Netherlands
Utrecht, Netherlands
Puerto Rico
San Juan, Puerto Rico
Russian Federation
Moscow N/A, Russian Federation
Moscow, Russian Federation
Saint-Petersburg, Russian Federation
St Petersburg, Russian Federation
Volgograd, Russian Federation
Alicante, Spain
Barcelona N/A, Spain
Barcelona, Spain
Bilbao, Spain
Cadiz N/A, Spain
Cuenca, Spain
Elche, Spain
Granada, Spain
Granollers, Spain
La Laguna, Spain
Logrono, Spain
Madrid N/A, Spain
Madrid, Spain
Malaga, Spain
Murcia, Spain
Málaga, Spain
Oviedo, Spain
Sabadell, Spain
Santiago De Compostela (La Cor, Spain
Sevilla N/A, Spain
Sevilla, Spain
Sta Cruz De Tenerife, Spain
Terrassa, Spain
Valencia N/A, Spain
Valencia, Spain
Vigo, Spain
Vitoria-Gasteiz, Spain
Göteborg, Sweden
Malmö, Sweden
Stockholm, Sweden
Kaohsiung City, Taiwan
Kaohsiung, Taiwan
Taipei, Taiwan
Ankara, Turkey
Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited

Additional Information:
Responsible Party: Tibotec Pharmaceuticals, Ireland Identifier: NCT00354627     History of Changes
Obsolete Identifiers: NCT00613236
Other Study ID Numbers: CR002743
TMC125-C214 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
First Posted: July 20, 2006    Key Record Dates
Last Update Posted: June 12, 2015
Last Verified: June 2015

Keywords provided by Tibotec Pharmaceuticals, Ireland:
Early Access Program (EAP)
failing multiple antiretroviral (ARV) regimens
limited to no treatment options

Additional relevant MeSH terms:
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents